{
  "nctId": "NCT02580305",
  "briefTitle": "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study",
  "officialTitle": "A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride",
  "protocolDocument": {
    "nctId": "NCT02580305",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-03-02",
    "uploadDate": "2023-04-17T07:22",
    "size": 30310264,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02580305/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 564,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-09",
    "completionDate": "2019-11-07",
    "primaryCompletionDate": "2019-11-05",
    "firstSubmitDate": "2015-10-17",
    "firstPostDate": "2015-10-20"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Has a diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria at least 1 year prior to the screening visit.\n* Has a score between 12 and 20 inclusive on the MMSE at the screening and baseline visits.\n* Has a MRI or CT scan performed within 12 months prior to screening with findings consistent with the diagnosis of dementia due to Alzheimer's disease without any other clinically significant comorbid pathologies.\n* Must be receiving treatment with stable doses of donepezil HCl and memantine HCl for at least 3 months prior to the screening visit\n* Availability of an eligible and reliable caregiver\n* Must be living in the community or an assisted living facility.\n* Must be ambulatory or ambulatory aided (use of cane or walker).\n* Is not pregnant or planning to become pregnant during the study.\n* Subject (or subject's legally acceptable representative) and caregiver must sign an Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Has a diagnosis of dementia due to other than Alzheimer's Disease\n* Is taking cholinesterase inhibitors other than donepezil HCl or taking doses of donepezil HCl other than 10 mg\n* Is taking doses of memantine HCl other than 10 mg bid or Namenda XRÂ® 28 mg qd.\n* Has uncontrolled cardiac disease or hypertension.\n* Has clinically significant renal or hepatic impairment.\n* Has cancer or a malignant tumor, untreated thyroid disorder or has a history of seizure disorder\n* Is treated or likely to require treatment during the study, with any medications prohibited by the study protocol.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "50 Years",
    "maximumAge": "85 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11)",
        "description": "Mean change from baseline at week 26 is assessed for ADAS-Cog11 score. The ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The scale ranges from 0 to 70, with higher scores indicate greater impairment.",
        "timeFrame": "Baseline to Week 26"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline to Week-26 in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)",
        "description": "Clinical Dementia Rating-Sum of Boxes (CDR-SB) - Sum of Boxes CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care.\n\nSeverity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.",
        "timeFrame": "Baseline to Week 26"
      },
      {
        "measure": "Change From Baseline to Week-26 in Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL)",
        "description": "The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score is a 23-item inventory.\n\nThe ADCS-ADL measures both basic and instrumental activities of daily living The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater disease severity.",
        "timeFrame": "Baseline to Week 26"
      },
      {
        "measure": "Change From Baseline to Week-26 in Neuropsychiatric Inventory (NPI)",
        "description": "Neuropsychiatric Inventory (NPI) 12 item - Total Score NPI assesses psychopathology in participants with dementia and other neurologic disorders.\n\nTotal score ranges from 12 to 144; higher scores indicate greater disease severity.",
        "timeFrame": "Baseline to Week 26"
      },
      {
        "measure": "Change From Baseline to Week-26 in Change in Mini Mental State Examination (MMSE)",
        "description": "Change in Mini-Mental State Examination (MMSE) - Total Score Minimum Score - 0, Maximum Score - 30. Higher score means better outcome.",
        "timeFrame": "Baseline to Week 26"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 59,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-21T22:34:02.810Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}